Cue Biopharma. Every tracked FinTwit mention of $CUE, newest first. 10 mentions since the first on Mar 15, 2026. See the price chart.
June 2026 · 5 mentions
Jun 17
InvestmentGuru — $CUE
What continues to stand out about $CUE is that this isn’t a one-drug story — it’s a platform story. Cue Biopharma’s Selective Immune Modulation platform is designed to mimic…↗
InvestmentGuru — 🧬 $CUE is becoming one of the more interesting micro-cap biotech turnaround stories on my watchlist. The company now has a ~$110M market cap, reported Q1 2026 collaboration revenu…↗
Jun 17
InvestmentGuru — $CUE — One Small-Cap Immunology Name I’m Watching Closely
This isn’t your typical biotech story.
Cue Biopharma is building a precision immunology platform designed to selectively…↗
Jun 17
InvestmentGuru — $CUE — 5 Reasons This Immunology Story Is Getting Attention
The immunology space is competitive, but Cue Biopharma is building a differentiated, precision-driven platform that con…↗
May 2026 · 4 mentions
May 19
InvestmentGuru — $CUE
Wrapping up the day still thinking about $CUE — at ~$110M market cap you’re getting a validated immunology platform, a Boehringer Ingelheim partnership worth up to $345M in m…↗
May 19
InvestmentGuru — $CUE
The part that doesn’t get enough attention:
Boehringer Ingelheim didn’t just partner with them. They keep paying milestones.
That’s big pharma saying the platform still w…↗
May 19
InvestmentGuru — $CUE — micro-cap biotech turnaround worth watching.
→ Market cap ~$110M
→ Collaboration revenue: $0.4M → $5.7M YoY
→ Net loss cut from $12.3M to $5.2M
→ $30M financing + Boehringe…↗
InvestmentGuru — 6 Peptide Biotech Stocks to watch for future.
$BCYC
•Tumor-targeting bicyclic peptides
•Oncology + peptide-drug conjugates
•Could attract major pharma buyouts if trials succeed…↗
— $CUE
One Small-Cap Immunology Name.
Cue Biopharma is building a precision immunology platform designed to selectively activate only disease-relevant T cells — potentially avoid…